Please assess the completion status of the following clinical trial:

Trial Title: A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet the following criteria to be enrolled in this study.~1. The patient is ≥18 years old at the time of informed consent.~2. The patient has a documented diagnosis of HAE type I or II. The diagnosis will be confirmed either by documented decreased C4 levels and/or immunogenic or functional C1-INH deficiency results (\<50% of normal levels) consistent with HAE types I and II or by medical history.~3. The current HAE attack must be in the cutaneous, abdominal and/or laryngeal (inclusive of laryngeal and pharyngeal) areas.~4. Cutaneous or abdominal HAE attacks must be moderate to very severe as determined by investigator global assessment at pre-treatment assessments~5. The patient must report at least 1 VAS score ≥ 30mm~6. The patient commences treatment within 6 hours of the attack becoming at least mild (laryngeal) or moderate (non-laryngeal) in severity, but not more than 12 hours after the onset of the attack.~7. Women of childbearing potential must have a negative urine pregnancy test and must use appropriate methods to prevent pregnancy during their participation in the study.~Exclusion Criteria:~Patients who meet any of the following criteria will be excluded from the study.~1. The patient has a diagnosis of angioedema other than HAE type I or II.~2. The patient has received previous treatment with icatibant.~3. The patient has participated in a clinical trial and has received treatment with another investigational medicinal product within the past 30 days.~4. The patient has received treatment with any pain medication since the onset of the current angioedema attack.~5. The patient has received replacement therapy (fresh frozen plasma \[FFP\], C1-INH products) less than 5 days (120 hours) from the onset of the current angioedema attack.~6. The patient is receiving treatment with angiotensin converting enzyme (ACE) inhibitors.~7. Evidence of coronary artery disease based on medical history or screening examination in particular unstable angina pectoris or severe coronary heart disease;~8. The patient has a serious concomitant illness or condition that, in the opinion of the Investigator, would be a contraindication for participation in the trial.~9. The patient is pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Single subcutaneous injection of matching placebo
- Icatibant (Type: EXPERIMENTAL): Single subcutaneous injection of icatibant, 30 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).